
Kane Biotech Inc.
KNE.VTSXVHealthcare● Active
$0.03
+$0.01(+16.67%)
Market Cap$5455710
P/E Ratio—
52W High$0.07
52W Low$0.03
Kane Biotech Inc.(KNE.V)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · KNE.V · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.43M | $2.08M | $0.15M | $0.16M | $1.61M |
| Cost of Revenue | $0.59M | $1.21M | $0.04M | $1.26M | $1.04M |
| Gross Profit | ($0.16M) | $0.87M | $0.11M | $1.41M | $0.57M |
| Gross Margin %(computed) | -38.18% | 41.91% | 73.48% | 901.68% | 35.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.87M | $1.95M | $1.29M | $1.05M | $1.38M |
| G&A Expenses | $0.00M | $3.08M | $2.41M | $3.72M | $4.07M |
| Total Operating Expenses | $2.95M | $4.80M | $3.47M | $4.78M | $5.45M |
| Operating Income | ($3.11M) | ($4.49M) | ($3.36M) | ($3.46M) | ($4.88M) |
| Operating Margin %(computed) | -727.40% | -215.96% | — | — | -303.75% |
| Interest Income | $0.02M | $0.00M | $0.01M | $0.02M | $0.12M |
| Interest Expense | $0.24M | $0.55M | $1.22M | $0.82M | $0.42M |
| Income Before Tax | ($2.83M) | ($4.47M) | ($4.56M) | ($4.02M) | ($4.85M) |
| Income Tax Expense | ($0.11M) | ($1.31M) | $0.00M | $0.00M | $0.00M |
| Net Income | ($2.72M) | ($3.02M) | ($5.03M) | ($3.89M) | ($4.60M) |
| Net Margin %(computed) | -636.00% | -145.35% | — | — | -286.39% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.02 | $-0.04 | $-0.03 | $-0.04 |
| Wtd Avg Shares | 162.22M | 133.91M | 140.26M | 120.70M | 112.60M |
| EBITDA | ($2.95M) | ($3.71M) | ($3.23M) | ($2.95M) | ($4.25M) |
| EBITDA Margin %(computed) | -689.37% | -178.17% | — | — | -264.08% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · CAD · M
深入了解Kane Biotech Inc.
关于Kane Biotech Inc.(KNE.V)损益表
Kane Biotech Inc.(KNE.V)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,KNE.V实现营收$0.00B,毛利润($0.00B)(毛利率-38.18%),净利润($0.00B)(净利率-636.00%)。
常见问题
KNE.V · 4 问Kane Biotech Inc.(KNE.V)2025财年营收为$0.00B,同比down79.4%。
KNE.V revenueKNE.V salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08